托伐普坦片可以治疗心衰吗,效果好吗？

Heart failure is one of the common diseases in cardiovascular medicine. With the acceleration of the aging process in our country, its incidence is getting higher and higher, and it has gradually become one of the main causes of death in the elderly. Almost all cardiovascular diseases will eventually lead to heart failure. Clinically, it is believed that the occurrence and development of the disease are related to factors such as infection, severe arrhythmia, overloaded heart, inappropriate activities, and emotions. If acute heart failure is not treated in time, it can range from disability to death, so it is extremely harmful to patients. Tolvaptan tablets have become very popular recently, and many patients have come to ask if they can treat heart failure and are they effective?

Can tolvaptan tablets treat heart failure?

Tolvaptan is a new type of diuretic that has diuretic and sodium-retaining effects and has a certain auxiliary therapeutic effect on patients with acute heart failure.

Tolvaptan tablets effects

86 patients with acute heart failure admitted to the hospital were selected as the research subjects. All patients were divided into a control group and a treatment group based on the principle of random grouping, with 43 cases in each group. The control group received intravenous infusion of cinpazide maleate injection, 40 mL added to 500 mL of normal saline, once/d. The treatment group took tolvaptan tablets orally on the basis of the control group, 1 tablet/time, 1 time/d. Both groups of patients were treated continuously for 15 days. The clinical efficacy of the two groups was observed, and the cardiac function, renal function and heart failure indicators of the two groups were compared.

Results: After treatment, the total effective rates of the control group and treatment group were 76.74% and 95.35% respectively, and the difference between the two groups was statistically significant (P<0.05). After treatment, the left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), glomerular filtration rate (GFR) and urine output in both groups were significantly increased, and the differences in the same group before and after treatment were statistically significant (P<0.05); and these observation indicators in the treatment group were significantly higher than those in the control group, and the differences between the two groups were statistically significant (P<0.05).

Conclusion: Tolvaptan tablets combined with cinepazide maleate injection has good clinical efficacy in the treatment of acute heart failure. It can improve cardiac function and renal function, regulate the levels of NT-proBNP, creatine kinase isoenzyme (CK-MB) and cardiac troponin (cTnl). It is safe and has certain clinical promotion and application value.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (if there are any errors or omissions, please help to correct them). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific drug guidelines, please consult the attending physician.

Recommended related articles: